# GALECTIN THERAPEUTICS INC (GALT)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/GALT/

- Reporting holders: 4
- Reported value: $54.6K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [ATWOOD & PALMER INC](https://holderbook.com/funds/1044929-atwood-palmer-inc/) | $38.8K | 10,000 | 0.0% | 5 |
| [CoreCap Advisors, LLC](https://holderbook.com/funds/1902501-corecap-advisors-llc/) | $15.1K | 3,890 | 0.0% | 9 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $644 | 166 | 0.0% | 1 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $19 | 5 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 4 | $54.6K |
| Q2 2026 | 102 | $85.9M |
| Q1 2026 | 102 | $44.8M |
| Q4 2025 | 100 | $54.7M |
| Q3 2025 | 85 | $46.0M |
| Q2 2025 | 88 | $23.6M |
| Q1 2025 | 94 | $16.0M |
| Q4 2024 | 102 | $26.5M |
| Q3 2024 | 85 | $36.2M |
| Q2 2024 | 74 | $23.9M |
| Q1 2024 | 60 | $19.3M |
| Q4 2023 | 67 | $12.4M |